SecBot SecBot
8-K ·Filed Aug 17, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001171843-26-005580
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

This is a product software upgrade announcement with no financial or guidance content, a routine operational update. Monitor upcoming quarterly filings for evidence of increased utilization or procedure volumes that could flow into revenue; no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.55
T+0 close · Aug 17, 2026 · via day close
Latest settled
+17.25%
T+60 · $7.68
Vs SPY
+20.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $6.55entry
  2. T+1 · 3mo ago +6.87%α +7.55% · $7.00
  3. T+5 · 3mo ago +3.82%α +5.01% · $6.80
  4. T+20 · 2mo ago −13.28%α −11.30% · $5.68
  5. T+60 · 7d ago +17.25%α +20.20% · $7.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical announced the introduction of its latest Treatment Delivery Console (TDC) software, which is being deployed across its TULSA-PRO installed base. The software adds real-time iMRI control and physician-requested UI improvements, with management stating it provides a roadmap for surgeons to achieve up to six TULSA procedures per day (up from a current reported capability of approximately four per day by some physicians). The filing contains no financial data, no guidance updates, and no preliminary results.

Key Facts

  • Profound introduced a new TDC software update deployed across the installed TULSA-PRO base.
  • Key new features: real-time iMRI control and physician-requested UI/hardware improvements.
  • CEO stated the software provides a roadmap for surgeons to achieve up to 6 TULSA procedures per system per day; a 'few' physicians already report performing up to 4 per day.
  • No financial figures, revenue guidance, or quantitative performance metrics were provided in the filing.

Financial Impact

No financial data provided in filing; potential for increased procedure throughput over time but no revenue impact disclosed.

Risk Factors

  • No financial/guidance data to evaluate materiality; software roadmap may not achieve intended utilization gains.
  • Competitive intensity in prostate ablation market may limit up-take or pricing power.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005580
Exhibit: exh_991.htm0001171843-26-005580
Document: 0001171843-26-005580-index-headers.html0001171843-26-005580
Document: 0001171843-26-005580-index.html0001171843-26-005580
Document: 0001171843-26-005580.txt0001171843-26-005580

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026